Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 11, 2007 - Issue 6
Submit an article Journal homepage
30
Views
2
CrossRef citations to date
0
Altmetric
Meeting Highlights

Inflammatory bowel diseases: meeting of the European Crohn’s Colitis Organization

1 – 3 March 2007, Innsbruck, Austria

Herbert Tilg Medical University Innsbruck, Department of Medicine, Anichstrasse 35, 6020 Innsbruck, Austria. [email protected]
Pages 853-856 | Published online: 15 May 2007

Bibliography

  • PODOLSKY DK: Inflammatory bowel disease. N. Engl. J. Med. (2002) 347(6):417-429.
  • HANAUER SB: Medical therapy for ulcerative colitis 2004. Gastroenterology (2004) 126(6):1582-1592.
  • TRAVIS SP, STANGE EF, LEMANN M et al.: European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut (2006) 55(Suppl. 1):i16-i35.
  • CAPRILLI R, GASSULL MA, ESCHER JC et al.: European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations. Gut (2006) 55(Suppl. 1):i36-i58.
  • TARGAN SR, HANAUER SB, VAN DEVENTER SJ et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N. Engl. J. Med. (1997) 337(15):1029-1035.
  • PRESENT DH, RUTGEERTS P, TARGAN S et al.: Infliximab for the treatment of fistulas in patients with Crohn’s disease. N. Engl. J. Med. (1999) 340(18):1398-1405.
  • HANAUER SB, FEAGAN BG, LICHTENSTEIN GR et al.: Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet (2002) 359(9317):1541-1549.
  • SCHNITZLER F, FIDDER H, FERRANTE M et al.: Long-term outcome of treatment with infliximab in 440 Crohn’s disease patients: Results from a single center cohort. J. Crohn’s Colitis Suppl. (2007) 1:1-55 (Abstract 01).
  • FIDDER H, SCHNITZLER F, FERRANTE M et al.: Long-term safety of infliximab in the treatment of inflammatory bowel disease: a single center cohort study. J. Crohn’s Colitis Suppl. (2007) 1:1-55 (Abstract 07).
  • VAN ASSCHE G, PAINTAUD G, MAGDELAINE C et al.: Concomitant immunosuppression does not impact on the outcome of maintenance infliximab therapy in Crohn’s disease: final results of the IMID trial. J. Crohn’s Colitis Suppl. (2007) 1:1-55 (Abstract 08).
  • MACKEY AC, GREEN L, LIANG LC, DINNDORF P, AVIGAN M: Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. (2007) 44(2):265-267.
  • HANAUER SB, SANDBORN WJ, RUTGEERTS P et al.: Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology (2006) 130(2):323-333.
  • SCHREIBER S, RUTGEERTS P, FEDORAK RN et al.: A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology (2005) 129(3):807-818.
  • LOFTUS EV, COLOMBEL JF, RUTGEERTS P et al.: Short-term adalimumab therapy improves quality of life in patients who had failed infliximab therapy: results from the GAIN trial. J. Crohn’s Colitis Suppl. (2007) 1:1-55 (Abstract 113).
  • FEAGAN B, BROWN M, GERLIER L, SCHREIBER S. Certolizumab pegol improves work productivity and the ability to perform daily activities in patients with Crohn’s disease: data from PRECISE 2. J. Crohn’s Colitis Suppl. (2007) 1:1-55 (Abstract 11).
  • COLOMBEL JF, HANAUER SB, SANDBORN WJ et al.: Certolizumab pegol is effective in patients regardless of CRP level and disease duration: data from PRECISE 2. J. Crohn’s Colitis Suppl. (2007) 1:1-55 (Abstract 018).
  • COLOMBEL SF, HANAUER SB, SANDBORN WJ et al.: Subcutaneous certolizumab pegol is effective in patients with prior infliximab exposure, or concomitant immunosuppressant or glucocorticoid treatment: data from PRECISE 2. J. Crohn’s Colitis Suppl. (2007) 1:1-55 (Abstract 019).
  • SCHREIBER S, FEAGAN B, HANAUER SB et al.: Subcutaneous certolizumab pegol is well tolerated by patients with active Crohn’s disease: results from two Phase III studies (PRECISE 1 and 2). J. Crohn’s Colitis Suppl. (2007) 1:1-55 (Abstract 21).
  • D’HAENS G, KOVACS A, VERGAUWE P et al.: Budesonide MMX is efficient and safe in patients with active left-sided ulcerative colitis. J. Crohn’s Colitis Suppl. (2007) 1:1-55 (Abstract 43).
  • GASSULL M, LICHTENSTEIN G, SANDBORN WJ et al.: MMX mesalazine is an effective treatment for men and women with mild-to-moderate, active ulcerative colitis. J. Crohn’s Colitis Suppl. (2007) 1:1-55 (Abstract 57).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.